GenFleet Therapeutics (Shanghai) Inc. (HKG:2595)

Hong Kong · Delayed Price · Currency is HKD

28.62

-0.08 (-0.28%)

Jun 18, 2026, 4:08 PM HKT

-34.95% (1Y)

Market Cap	10.60B
Revenue (ttm)	144.96M +24.4%
Net Income	-2.00B
EPS	-6.75
Shares Out	370.37M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	863,414
Open	27.96
Previous Close	28.70
Day's Range	27.80 - 29.50
52-Week Range	19.60 - 52.90
Beta	n/a
Analysts	Buy
Price Target	59.68 (+108.53%)
Earnings Date	Mar 24, 2026

About HKG:2595

GenFleet Therapeutics (Shanghai) Inc., a biopharmaceutical company, develops treatment options in the fields of oncology, autoimmune, and inflammatory diseases in the United States. The company develops GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C in a Phase III trial for the treatment of pancreatic cancer, as well as in Phase II trials for the treatment of non-small cell lung cancer (NSCLC) and BTC, and in a Phase I trial for the treatment of solid tumors; GFH925, a small molecule selective inhibit... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2017

Country China

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2595

Full Company Profile

Financial Performance

In 2025, HKG:2595's revenue was 130.27 million, an increase of 24.42% compared to the previous year's 104.70 million. Losses were -1.79 billion, 164.8% more than in 2024.

Financial numbers in CNY Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 2595 stock is "Buy." The 12-month stock price target is $59.68, which is an increase of 108.53% from the latest price.

Price Target

$59.68

(108.53% upside)

Analyst Consensus: Buy

Stock Forecasts